Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PTO Affirms Shire’s Lialda Patent; First Decision In Kyle Bass IPR Case

Executive Summary

Patent board has instituted 19 other inter partes review proceedings sought by the hedge fund manager and declined to institute 14.

You may also be interested in...



US Patent Battles May Resume Next Congress; Reps Press For IPR Reform

10 New York representatives urge PTO to deny access to the inter partes review process to hedge funds and non-practitioners; generic companies join non-practicing entity Neptune Generics in challenging Lilly’s Almita patent.

Patent Score Card: Kyle Bass Gets 17 IPR Reviews Granted, 14 Denied

Bass wins review of four Acorda patents based on SEC registration filing; Patent Trial and Appeal Board declines to institute inter partes review of Enbrel patent and Insys' Subsys patents but okays trial on Juxtapid patents.

Supreme Court Seems To Support Government’s Later Dismissal Of False Claims Act Cases

Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel